Antibodies, Monoclonal, Murine-DerivedTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsSalvage TherapyRemission InductionHodgkin DiseaseRecurrenceTransplantation, AutologousHematopoietic Stem Cell TransplantationCytarabineCyclophosphamideLymphoma, Non-HodgkinThiotepaEtoposideDrug Resistance, NeoplasmMelphalanTransplantation ConditioningMultiple MyelomaTransplantation, HomologousCombined Modality TherapyAntineoplastic AgentsVincristineAntibodies, MonoclonalAnemia, RefractoryDisease-Free SurvivalRefractory Period, ElectrophysiologicalLymphoma, FollicularSurvival RatePrednisoneDrug Administration SchedulePrognosisMethotrexateSurvival AnalysisLymphoma, Large B-Cell, DiffuseBone Marrow TransplantationDrug ResistanceNeoplasm Recurrence, LocalImmunosuppressive AgentsRetrospective StudiesStem Cell TransplantationLeukemia, Myeloid, AcuteDoxorubicinGraft vs Host DiseaseAnemia, Refractory, with Excess of BlastsFollow-Up StudiesClinical Trials as TopicTime FactorsDisease ProgressionThalidomideInfusions, IntravenousAnticonvulsantsTreatment FailureRefractory Period, PsychologicalBoronic AcidsEpilepsyPyrazinesMaximum Tolerated DoseDose-Response Relationship, DrugDrug EvaluationAnemia, SideroblasticPain, IntractableArabinonucleosidesEpilepsies, PartialVidarabineHeart Conduction SystemPiracetamDrug Therapy, CombinationMyelodysplastic SyndromesAtrioventricular NodeAnti-Arrhythmia AgentsCardiac Pacing, ArtificialThrombocytopeniaNeoplasmsAscitesRetreatment